Karachi: GlaxoSmithKline Pakistan Limited (GLAXO) held a corporate briefing session to discuss its financial performance for 2025 and future outlook. Despite facing challenges such as increased API costs and competition, the company reported a 9% growth in turnover, reaching Rs66 billion, and maintained its position as a leader in the Pakistani pharmaceutical market.
According to JS Global, GLAXO's management highlighted that while the increase in API costs aligns with rising drug prices, the company is positioned to maintain existing gross margins. However, persistent volatility could increase freight costs, especially since APIs are sourced primarily from India and China. The company also faces exposure to rupee devaluation due to dollar-linked costs.
In 2025, GLAXO experienced a 10-12% decline in volumes, attributed to price hikes and competition, although revenue increased due to price adjustments in its essential and non-essential portfolios. The company holds a 9% volumetric share and a 6% value share in the market, with institutional sales constituting 7-8% of total sales.
The top five brands, including Vates and Augmentin, contributed significantly to revenue. Management noted a strategic move away from low-margin tenders to ensure sustainability, and although promotional allowances decreased due to improved local profitability, the company continues to expand its vaccine offerings. Looking ahead, GLAXO is focusing on tax rationalization to mitigate the impact of the current high tax regime on its earnings.
The post GlaxoSmithKline Pakistan Reports Growth Amid Challenges in 2025 appeared first on Pakistan Business News.